Hugo M Horlings
Overview
Explore the profile of Hugo M Horlings including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
100
Citations
9398
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Greenwald N, Nederlof I, Sowers C, Ding D, Park S, Kong A, et al.
bioRxiv
. 2025 Feb;
PMID: 39975273
Immune checkpoint inhibition (ICI) has fundamentally changed cancer treatment. However, only a minority of patients with metastatic triple negative breast cancer (TNBC) benefit from ICI, and the determinants of response...
2.
Zelisse H, van Gent M, Mom C, de Ridder S, Snijders M, Heeling M, et al.
Ann Diagn Pathol
. 2024 Nov;
74:152411.
PMID: 39591762
Fundamental and translational research in ovarian cancer aims to enhance understanding of disease mechanisms and improve treatment and survival outcomes. To support this, we established the Dutch multicenter, interdisciplinary Archipelago...
3.
Gao Y, Ventura-Diaz S, Wang X, He M, Xu Z, Weir A, et al.
Nat Commun
. 2024 Nov;
15(1):9613.
PMID: 39511143
Multi-modal image analysis using deep learning (DL) lays the foundation for neoadjuvant treatment (NAT) response monitoring. However, existing methods prioritize extracting multi-modal features to enhance predictive performance, with limited consideration...
4.
Nederlof I, Isaeva O, de Graaf M, Gielen R, Bakker N, Rolfes A, et al.
Nat Med
. 2024 Sep;
30(11):3223-3235.
PMID: 39284953
Immune checkpoint inhibition (ICI) with chemotherapy is now the standard of care for stage II-III triple-negative breast cancer; however, it is largely unknown for which patients ICI without chemotherapy could...
5.
Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial
Opdam M, van Rossum A, Hoogstraat M, Bounova G, Horlings H, van Werkhoven E, et al.
iScience
. 2024 Aug;
27(8):110425.
PMID: 39206149
The primary objective of the prospective, randomized, multicenter, phase 3 biomarker Microarray Analysis in breast cancer to Taylor Adjuvant Drugs Or Regimens trial (MATADOR: ISRCTN61893718) is to generate a gene...
6.
Geurts V, Balduzzi S, Steenbruggen T, Linn S, Siesling S, Badve S, et al.
JAMA Oncol
. 2024 Jun;
10(8):1077-1086.
PMID: 38935352
Importance: The absolute benefit of chemotherapy for all patients with stage I triple-negative breast cancer (TNBC) is unclear, and biomarkers are not currently available for selecting patients with an excellent...
7.
van Wagensveld L, Van Nyen T, Annibali D, Sonke G, Kruitwagen R, Amant F, et al.
Oncologist
. 2024 Jun;
29(9):e1231-e1234.
PMID: 38920311
Introduction: High-grade serous ovarian cancer (HGSOC) is characterized by high mortality and prevalent recurrences. This study investigates the prognostic value of phosphoglycerate dehydrogenase (PHGDH) in HGSOC which has been linked...
8.
Aronson S, Walker C, Thijssen B, Van de Vijver K, Horlings H, Sanders J, et al.
Br J Cancer
. 2024 Jun;
131(3):565-576.
PMID: 38866963
Background: Hyperthermic intraperitoneal chemotherapy (HIPEC) improves survival in patients with Stage III ovarian cancer following interval cytoreductive surgery (CRS). Optimising patient selection is essential to maximise treatment efficacy and avoid...
9.
Zelisse H, de Ridder S, van Gent M, Mom C, Wisman G, Roes E, et al.
Biopreserv Biobank
. 2024 Apr;
22(6):568-577.
PMID: 38682281
Biobanks play a crucial role in fundamental and translational research by storing valuable biomaterials and data for future analyses. However, the design of their information technology (IT) infrastructures is often...
10.
Jahangir C, Page D, Broeckx G, Gonzalez C, Burke C, Murphy C, et al.
J Pathol
. 2024 Jan;
262(3):271-288.
PMID: 38230434
Recent advances in the field of immuno-oncology have brought transformative changes in the management of cancer patients. The immune profile of tumours has been found to have key value in...